Please login to the form below

Not currently logged in
Email:
Password:

Amryt

This page shows the latest Amryt news and features for those working in and with pharma, biotech and healthcare.

NHS England says yes to Roche's Hemlibra

NHS England says yes to Roche's Hemlibra

Amryt Pharma’s Lojuxta (lomitapide) for homozygous familial hypercholesterolaemia (HoFH) was ranked as a Level 3.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Amryt Pharma appoints Jordi Casals as head of Europe Amryt Pharma appoints Jordi Casals as head of Europe

    Dr Joe Wiley, chief executive officer of Amryt, said: “I am pleased to welcome Jordi to our senior management team as the company’s head of Europe. ... His significant commercial experience of European markets will help us to drive and further

  • Amryt Pharma appoints new regulatory affairs head Amryt Pharma appoints new regulatory affairs head

    Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin. ... Her new role will see her take responsibility for engagement with regulatory agencies and she will examine opportunities to pursue new

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics